UBS cuts CVS Health target to $118; backs Thyme Care funding
UBS trimmed its price target on CVS Health to $118 from $126. CVS is also investing in Thyme Care’s $125M+ Series E, valuing the startup above $2B.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.